PDL BioPharma (PDLI) : During the past 4 weeks, traders have been relatively bearish on PDL BioPharma (PDLI), hence the stock is down -16.09% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.01% relative to the S&P 500. The 4-week change in the price of the stock is -15.22% and the stock has fallen -5.96% in the past 1 week.
The stock has recorded a 20-day Moving Average of 15.75% and the 50-Day Moving Average is 13.09%. PDL BioPharma (NASDAQ:PDLI): On Fridays trading session , Opening price of the stock was $2.93 with an intraday high of $2.98. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $2.84. However, the stock managed to close at $2.84, a loss of 3.40% for the day. On the previous day, the stock had closed at $2.94. The total traded volume of the day was 1,567,099 shares.
The company Insiders own 1.1% of PDL BioPharma shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 4.4% . Institutional Investors own 78.64% of PDL BioPharma shares. During last six month period, the net percent change held by insiders has seen a change of 4.4%.
PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.